MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.390
+0.030
+2.21%
After Hours: 1.380 -0.01 -0.72% 16:00 08/03 EDT
OPEN
1.390
PREV CLOSE
1.360
HIGH
1.400
LOW
1.370
VOLUME
1.79M
TURNOVER
--
52 WEEK HIGH
2.300
52 WEEK LOW
0.4990
MARKET CAP
171.20M
P/E (TTM)
-0.9006
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OTLK stock price target is 6.05 with a high estimate of 9.00 and a low estimate of 3.250.

EPS

OTLK News

More
Apellis Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/09 06:44
Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of ONS-5010 / LYTENAVA (bevacizumab-vikg)
GlobeNewswire · 07/07 13:05
Outlook Therapeutics completes patient enrollment for NORSE 2 study of ONS-5010
Seeking Alpha - Article · 07/07 13:00
Outlook Therapeutics Completes Patient Enrollment For NORSE 2 Study Of ONS-5010 / LYTENAVA (bevacizumab-vikg)
Benzinga · 07/07 12:11
FDA rejects Allergan application for wet AMD drug
Seeking Alpha - Article · 06/26 10:33
Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7%
Zacks · 06/25 14:43
Outlook Therapeutics Announces Closing of $10.2 Million Financing Priced At-The-Market Under Nasdaq Rules
GlobeNewswire · 06/25 13:05
Outlook Therapeutics Announces $11.2 Million Financings Priced At-The-Market Under Nasdaq Rules
GlobeNewswire · 06/23 13:00

Industry

Biotechnology & Medical Research
+3.46%
Pharmaceuticals & Medical Research
+1.95%

Hot Stocks

Symbol
Price
%Change

About OTLK

Outlook Therapeutics, Inc., formerly Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab.
More

Webull offers kinds of Outlook Therapeutics Inc stock information, including NASDAQ:OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.